Article

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Author(s):

Bonnie Gillis

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Marlyn Mayo, MD: Improving Pruritus Management in PBC Care
Related Content
A New Era for NMIBC: How a Decade of Progress is Reshaping Treatment | Credit: HCPLive
December 12th 2024

A New Era for NMIBC: How a Decade of Progress is Reshaping Treatment

Hannah Clarke
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Lebrikizumab for Atopic Dermatitis Results in Long-Term Improvements Over 152 Weeks
December 12th 2024

Lebrikizumab for Atopic Dermatitis Results in Long-Term Improvements Over 152 Weeks

Tim Smith
Kidney Compass default thumbnail with podcast logo and headshots of hosts Brendon Neuen and Shikha Wadhwani.
December 11th 2024

Kidney Compass: Future of PARASOL and FSGS Management

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Sanna Nybacka | Credit: Sanna Nybacka on LinkedIn
December 12th 2024

Lower Diet Diversity, Quality Linked to More Severe IBS Symptoms

Abigail Brooks, MA
Bulevirtide Monotherapy Well-Tolerated, Safe for Chronic Hepatitis Delta at Week 48
December 11th 2024

Bulevirtide Monotherapy Well-Tolerated, Safe for Chronic Hepatitis Delta at Week 48

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.